D. E. Shaw & Co., Inc. Tyra Biosciences, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TYRA
# of Institutions
98Shares Held
43.5MCall Options Held
353KPut Options Held
1.1K-
Ra Capital Management, L.P. Boston, MA10.4MShares$146 Million3.41% of portfolio
-
Boxer Capital, LLC San Diego, CA6.45MShares$90.3 Million8.05% of portfolio
-
Bvf Inc San Francisco, CA4.66MShares$65.3 Million3.48% of portfolio
-
Canaan Partners Xi LLC Menlo Park, CA4.41MShares$61.7 Million97.89% of portfolio
-
Nextech Invest Ag4.06MShares$56.8 Million15.55% of portfolio
About Tyra Biosciences, Inc.
- Ticker TYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,973,600
- Market Cap $588M
- Description
- Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...